Breast Cancer - ModernMedicine
www.fgks.org   »   [go: up one dir, main page]

Breast Cancer

Editor's Choice
Effective Health Care Clinician Guides
Making good decisions requires that physicians have reliable and practical data. Comparative effectiveness reviews and objective findings on different medical interventions and strategies, as provided by the Agency for Healthcare Research and Quality in its Effective Health Care Program, can help physicians make the most informed choices among treatment options.
LATEST ARTICLES
New BREAST-Q module helps manage patients' anticipations of reconstructive surgery
A new module of the BREAST-Q questionnaire enables plastic and reconstructive surgeons to gauge patient expectations related to reconstructive breast surgery. Andrea Pusic, M.D., M.H.S., F.R.C.S.C., says that when she initially consults with new patients, "I spend 45 minutes to an hour with them. During that consultation, I can easily spend 30 or more minutes talking about different surgical options and how the surgery will be done technically. Then I spend 10 or 15 minutes talking about everything that can go wrong."
FDA revokes breast cancer indication for bevacizumab
FDA Commissioner Margaret A. Hamburg, MD, announced the agency's decision to revoke the breast cancer indication for bevacizumab (Avastin), noting that the benefits do not outweigh the potentially life-threatening side effects, such as heart attack or heart failure, high blood pressure, bleeding and hemorrhaging, and the development of perforations in different parts of the body, such as the nose, stomach, and intestines.
Effective Health Care Clinician Guides
Making good decisions requires that physicians have reliable and practical data. Comparative effectiveness reviews and objective findings on different medical interventions and strategies, as provided by the Agency for Healthcare Research and Quality in its Effective Health Care Program, can help physicians make the most informed choices among treatment options.
Blue Shield of California stops coverage of bevacizumab for breast cancer
Blue Shield of California will no longer pay for the use of bevacizumab (Avastin, Genentech, a member of the Roche Group) to treat metastatic breast cancer, according to The New York Times.
FDA's Hamburg to make final decision on Avastin's indication for metastatic breast cancer
In the face of dozens of pink-clad demonstrators at the gates of FDA and many heartfelt pleas from women with metastatic breast cancer, an advisory committee to the agency voted unanimously at the end of June to hold firm in its recommendation that approval for Avastin (bevacizumab) for breast cancer be withdrawn.
eSamples check closet
eSamples check closet
Practice ToolsPractice Tools
Coding Counselor
Coding Counselor

Simple and accurate ICD-9 code search. Start Here

Patient Education
Patient Education

Print customized patient education handouts. Start Here

Dermatology Diagnosis
Dermatology Diagnosis

Identify skin diseases by age, gender, location. Start Here

AHRQ Clinical Guidelines
AHRQ Clinical Guidelines

Objective findings on medical interventions. Start Here



Click here